GSK plc reported Q2 2025 sales of £8.0 billion, a 1% increase, driven by a 15% rise in Specialty Medicines. The filing highlights strong performances in Oncology (42% growth) and HIV (12% growth); important regulatory approvals are expected between 2025 and 2031.